YD Bio Ltd director Chang Kochi reported equity compensation activity involving Restricted Share Units (RSUs) and ordinary shares. On June 30, 2026, Kochi exercised 5,749 RSUs into the same number of ordinary shares at a stated price of $0.0000 per share, increasing direct holdings to 7,830 ordinary shares.
On the same date, Kochi also received a new grant of 5,749 RSUs with each RSU representing one ordinary share of YD Bio Ltd. According to the equity plan, the RSUs relate to a target aggregate grant date fair value of $60,000, vesting in four equal quarterly installments determined using a seven trading-day volume-weighted average price.
YD Bio Limited filed a post-effective amendment to its Form F-1 to register 11,436,270 Ordinary Shares issuable upon exercise of Public Warrants.
The prospectus also covers resale by selling shareholders of up to 58,571,199 Ordinary Shares and 3,136,056 Ordinary Shares issuable upon exercise of Private Warrants. The company will not receive proceeds from resale by the selling shareholders; however, cash exercise of all outstanding warrants (aggregate 14,572,326) would yield gross proceeds of up to $167,581,749. The filing updates the registration to reflect the Company’s Form 20-F for the fiscal year ended December 31, 2025 and states no additional securities are being registered under this amendment.
YD Bio Limited reported full-year 2025 net revenue of $596,817, up 17% from 2024, driven mainly by higher pharmaceutical sales, including Keytruda and new product launches. Gross profit rose to $167,410, but the sales mix shifted toward lower-margin drugs and peripherals, pressuring margins.
Total operating expenses surged to $5.4 million from $1.6 million, reflecting higher professional fees, a $1.1 million increase in research and development tied to licensed patents and know‑how, and a $1.3 million rise in staff costs as the business expanded.
Net loss widened sharply to $8.3 million from $1.4 million, mainly due to a $3.2 million adverse change in fair value of warrant liabilities and higher operating costs. Cash and cash equivalents increased to $6.0 million from $3.1 million, supported by a $13.9 million equity raise. The company ended 2025 with warrant liabilities of $14.99 million and a shareholders’ equity deficit of $2.86 million.
YD Bio Limited, a Cayman Islands company listed on the Nasdaq Global Market, files its annual report describing a young, loss-making healthcare business built around cancer blood tests and ophthalmology drugs. As of December 31, 2025, it had 70,789,261 ordinary shares and 15,142,911 warrants outstanding.
The report explains that YD Bio was created through a Business Combination with Breeze Holdings Acquisition Corp. and now owns all shares of YD Biopharma. Management discloses recurring losses, significant negative cash flow and substantial doubt about the company’s ability to continue as a going concern without new financing.
Key risks include dependence on critical IP licenses from EG BioMed and 3D Global, reliance on third‑party manufacturers, heavy revenue concentration in three major customers accounting for about 53.7% of 2025 revenue, and limited public‑company experience in the management team.
The company highlights extensive regulatory and reimbursement uncertainty: its cancer tests are Laboratory Developed Tests, future FDA oversight could change, and commercialization would require complex U.S. and foreign approvals and clinical trials. YD Bio is also exposed to Taiwan‑specific geopolitical and natural disaster risks, intellectual property disputes, potential PFIC and U.S. tax issues, and Nasdaq listing and dilution risks from public and private warrants.
YD Bio Ltd director Lu Shao-Ta updated his initial ownership report through an amended Form 3. The amendment adds disclosure of 51,151 Ordinary Shares held indirectly through his spouse that were previously omitted from his original Form 3 and one subsequent Form 4. This change reflects a correction in reported holdings, not a new share transaction.
YD Bio Ltd director Lu Shao-Ta reported equity compensation activity involving restricted share units (RSUs) that settled into ordinary shares. On March 31, 2026, he received 2,081 RSUs for no cash cost, each representing a right to one ordinary share. The same day, these RSUs were exercised and converted into 2,081 ordinary shares at a conversion price of $0.00 per share, leaving him with 2,081 ordinary shares from this grant and no remaining RSUs from this tranche. The award is part of a broader $60,000 RSU grant under YD Bio’s equity incentive plan, scheduled to vest in four equal quarterly installments based on the stock’s seven‑day volume‑weighted average price before each vesting date.
YD Bio Ltd director Chang Kochi reported equity compensation activity involving restricted share units. On March 31, 2026, Kochi received 2,081 restricted share units, each representing a right to one ordinary share.
The same day, 2,081 RSUs were exercised and converted into 2,081 ordinary shares at a price of $0.0000 per share, leaving 2,081 ordinary shares held directly after the transactions. The award was granted under the YD Bio Limited Equity Incentive Plan with an aggregate target grant date fair value of $60,000, vesting in four equal quarterly installments of $15,000 each based on a seven trading-day volume-weighted average price.
YD Bio Ltd director Lu Shao-Ta has filed an initial Form 3 insider ownership report for YD Bio Ltd. The filing lists no reportable transactions or holdings, indicating this is an initial regulatory disclosure of insider status rather than a record of recent trading activity.
YD Bio Ltd director Chang Kochi filed an initial Form 3 reporting status as an insider of YD Bio Ltd (ticker YDES). The filing lists Kochi as a director and not a ten percent owner. No share transactions or derivative holdings are reported in this disclosure.